Zobrazeno 1 - 10
of 277
pro vyhledávání: '"V F, Semiglazov"'
Autor:
D. A. Enaldieva, P. V. Krivorotko, E. N. Imyanitov, E. K. Zhiltsova, R. V. Donskikh, L. F. Shaikhelislamova, L. P. Gigolaeva, V. F. Semiglazov
Publikováno v:
Успехи молекулярной онкологии, Vol 10, Iss 3, Pp 8-14 (2023)
BRCA-associated triple-negative breast cancer (TNBC) is characterized by high sensitivity to DNA-damaging cytotoxic drugs. The use of well-known BRCA1/2-specific antitumor agents – platinum derivatives and PARP inhibitors – has been discussed for
Externí odkaz:
https://doaj.org/article/c0e113ef1add4fcf8c95f52edf7214f0
Autor:
V. M. Merabishvili, V. F. Semiglazov, A. V. Komiakhov, T. Yu. Semiglazova, P. V. Krivorotko, А. M. Belyaev
Publikováno v:
Опухоли женской репродуктивной системы, Vol 19, Iss 3, Pp 16-24 (2023)
Background. Breast cancer is the main cause of morbidity and mortality of the female population among economically developed countries, including in Russia. Despite the continued increase in morbidity, mortality is decreasing, which is confirmed by a
Externí odkaz:
https://doaj.org/article/026f70f8695d4c6f9f85d908899efae1
Autor:
R. M. Paltuev, O. A. Volynshchikova, Sh. R. Abdullaeva, S. N. Aleksakhina, A. S. Artemyeva, E. A. Baychorov, S. Yu. Bakharev, Yu. A. Belaya, A. A. Bozhok, V. A. Vasin, V. I. Vladimirov, A. Yu. Vorontsov, E. A. Gaysina, A. A. Gofman, V. N. Dmitriev, E. N. Imyanitov, V. V. Klimenko, A. V. Komyakhov, M. M. Konstantinova, M. V. Kopp, A. G. Kudaybergenova, I. A. Lalak, D. L. Matevosyan, N. M. Mudzhiri, O. V. Poltareva, O. I. Sevryukova, V. F. Semiglazov, T. Yu. Semiglazova, M. M. Urezkova, A. S. Chichkanova, L. A. Churilova, M. V. Shomova
Publikováno v:
Опухоли женской репродуктивной системы, Vol 19, Iss 3, Pp 30-36 (2023)
Background. Individual molecular characteristics of a tumor can serve as a basis for a tailored approach to therapy, prediction of the disease course and outcome, and timely treatment correction in cancer patients. Tumor genomic profiling allows for
Externí odkaz:
https://doaj.org/article/bb685938706842a0aee783498c6077ee
Publikováno v:
Опухоли женской репродуктивной системы, Vol 19, Iss 2, Pp 82-88 (2023)
Background. New biomarkers of breast cancer are actively being studied to used them for breast cancer prognosis and develop optimal approaches to therapy. FOXA1 is one of these factors whose prognostic value for breast cancer has been analyzed in sev
Externí odkaz:
https://doaj.org/article/55d03915007f44d28501147154d0a58a
Publikováno v:
Опухоли женской репродуктивной системы, Vol 19, Iss 2, Pp 89-93 (2023)
Aim. To evaluate the prognostic value of CD4+ in patients with T1–2N0M0 breast cancer.Materials and methods. We performed a quantitative assessment of CD4+ T-lymphocytes in tumor stromal cells and determined the prognostic parameter using the metho
Externí odkaz:
https://doaj.org/article/c745e3a1ae0d4d6aaab5046f0a547b6a
Autor:
R. M. Paltuev, A. G. Kudaybergenova, V. F. Semiglazov, A. S. Artemyeva, T. Yu. Semiglazova, A. V. Komyakhov, O. A. Volynshchikova, V. V. Klimenko, M. M. Urezkova
Publikováno v:
Опухоли женской репродуктивной системы, Vol 19, Iss 1, Pp 56-68 (2023)
Aim. To increase the efficacy of systemic breast cancer therapy and reduce inappropriate prescriptions using individual immunohistochemical tumor characteristics, as well as to develop prognostic scales to ensure a tailored approach to adjuvant syste
Externí odkaz:
https://doaj.org/article/0912cd61a86340dd8c2b80d35f9f8d94
Autor:
R. M. Paltuev, S. N. Aleksakhina, A. S. Artemyeva, E. A. Baychorov, S. Yu. Bakharev, A. A. Bozhok, V. A. Vasin, V. I. Vladimirov, O. A. Volynshchikova, A. Yu. Vorontsov, E. A. Gaysina, A. A. Hoffman, E. N. Imyanitov, V. V. Klimenko, A. V. Komyakhov, M. M. Konstantinovа, M. V. Kopp, A. G. Kudaybergenova, I. A. Lalak, D. L. Matevosyan, N. M. Mudzhiri, O. V. Poltareva, O. I. Sevryukova, V. F. Semiglazov, T. Yu. Semiglazova, M. M. Urezkova, L. A. Churilova
Publikováno v:
Опухоли женской репродуктивной системы, Vol 19, Iss 1, Pp 69-81 (2023)
Background. Breast cancer is one of the most common female malignancies. Molecular diagnostic methods of tumor profiling allow us to analyze individual tumor characteristics, identify new prognostic and predictive markers. Aim. To increase the effica
Externí odkaz:
https://doaj.org/article/cc538d9ba3a84480917cd97d5f495115
Autor:
D. A. Enaldieva, P. V. Krivorotko, E. N. Imyanitov, E. K. Zhiltsova, R. V. Donskikh, A. P. Sokolenko, L. F. Shaykhelislamova, T. T. Tabagua, L. P. Gigolaeva, A. V. Komyakhov, K. S. Nikolaev, K. Yu. Zernov, S. S. Ereshchenko, R. M. Paltuev, A. A. Bessonov, A. S. Artemyeva, R. S. Pesotskiy, N. S. Amirov, A. S. Emelyanov, V. V. Mortada, Ya. I. Bondarchuk, V. V. Semiglazov, T. Yu. Semiglazova, V. F. Semiglazov, A. M. Belyaev
Publikováno v:
Опухоли женской репродуктивной системы, Vol 19, Iss 1, Pp 48-55 (2023)
Background. BRCA-associated triple negative breast cancer (TNBC) is considered one of the most aggressive subtypes of breast cancer with high sensitivity to chemotherapy, which leads to increased interest in finding new treatment options for patients
Externí odkaz:
https://doaj.org/article/f7969acdde894223bd4331d72b66866d
Autor:
Ya. I. Bondarchuk, E. K. Zhiltsova, P. V. Krivorotko, R. S. Pesotskiy, A. S. Emelyanov, T. T. Tabagua, L. P. Gigolaeva, S. S. Yereshchenko, A. V. Komyakhov, K. S. Nikolaev, K. Yu. Zernov, V. V. Semiglazov, R. M. Paltuev, V. V. Mortada, L. F. Shaykhelislamova, D. A. Enaldieva, N. S. Amirov, V. S. Channov, A. S. Artemyeva, A. V. Chernaya, R. Kh. Ulyanova, V. F. Semiglazov
Publikováno v:
Опухоли женской репродуктивной системы, Vol 18, Iss 4, Pp 43-51 (2023)
Background. Surgery is fundamental in complex and combined approach in the treatment of the early breast cancer. It is a common fact, that absence of tumor cells in the resection margin is the main indicator of oncological safety of the breast-conser
Externí odkaz:
https://doaj.org/article/b0b1ea7f79e54b3197715ab491a1c07a
Autor:
P. V. Krivorotko, V. V. Mortada, R. S. Pesotskiy, A. S. Artemyeva, A. S. Emelyanov, S. S. Ereshchenko, G. A. Dashyan, N. S. Amirov, T. T. Tabagua, L. P. Gigolaeva, A. V. Komyakhov, K. S. Nikolaev, M. M. Mortada, K. Yu. Zernov, E. K. Zhiltsova, V. O. Smirnova, Ya. I. Bondarchuk, D. A. Enaldieva, S. N. Novikov, E. A. Busko, A. V. Chernaya, P. I. Krzhivitskiy, R. M. Paltuev, T. Yu. Semiglazova, V. F. Semiglazov, A. M. Belyaev
Publikováno v:
Опухоли женской репродуктивной системы, Vol 18, Iss 3, Pp 29-39 (2022)
Background. Achieving a pathologic complete response (pCR) after neoadjuvant systemic therapy (NST) is a predictive factor for improving disease free and overall survival. In triple negative (TN) and HER2-positive breast cancer (BC), the pCR rate exc
Externí odkaz:
https://doaj.org/article/1dba194b85a7496f8bacea07c8744896